Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
Thomas P. Monath, Jeroen Kortekaas, Douglas M. Watts, Rebecca C. Christofferson, Angelle Desiree LaBeaud, Brian Gowen, Clarence J. Peters, Darci R. Smith, Robert Swanepoel, John C. Morrill, Thomas G. Ksiazek, Phillip R. Pittman, Brian H. Bird, George Bettinger
Dive into the research topics of 'Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile'. Together they form a unique fingerprint.